A Src/Abl kinase inhibitor, bosutinib, downregulates and inhibits PARP enzyme and sensitizes cells to the DNA damaging agents

BALLAR KIRMIZIBAYRAK P., İLHAN R., Yilmaz S., Gunal S., ERBAYKENT TEPEDELEN B.

TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, cilt.43, sa.2, ss.101-109, 2018 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 43 Sayı: 2
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1515/tjb-2017-0095
  • Dergi Adı: TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.101-109
  • Anahtar Kelimeler: PARP inhibitor, PARylation, Bosutinib, Multi-kinase inhibitor, Chemosensitizer, POLY(ADP-RIBOSE) POLYMERASE-1 INHIBITOR, SKI-606 BOSUTINIB, BREAST-CANCER, GROWTH, DEATH, ACTIVATION, PROSTATE, INVASION, PATHWAY, STRESS
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Background: Poly(ADP-ribosyl)ation (PARylation) catalyzed mainly by PARP1 is a highly regulated posttranslational modification associated with several pathways in cellular physiology and genotoxic deoxyribonucleic acid (DNA) damage response. PAR polymers and PARP enzyme function in DNA integrity maintenance and several PARP inhibitors have entered clinical phase studies for cancer therapies.